Free Access
Tableau I.
Récapitulatif des essais cliniques de phase II et III utilisant des virus oncolytiques pour le traitement du cancer. IT : intratumoral ; IV : intraveineux ; IA : intra-artériel.
| Virus | Nom du virus oncolytique (compagnie) | Modification | Phase de l'essai clinique | Types de cancer | Voie d’injection | Combinaison |
|---|---|---|---|---|---|---|
| Virus de l'herpes simplex | OncoVEX/Talimogene | GM-CSF ; ICP 47 (-) ; ICP 34.5 (-) | III | Mélanome | IT | – |
| Laherparepvec (Amgen) | II | Cervico-facial | ||||
| IIb | Carcinome hépatocellulaire | IV | ||||
| Virus de la vaccine | JX-594 (Jennerex) | GM-CSF ; TK (-) | – | |||
| II | Carcinome hépatocellulaire | IT | ||||
| Cancer colorectal | ||||||
| III | Cervico-facial | |||||
| Cancer du poumon | ||||||
| Réovirus | Reolysin (Oncolytics biotech) |
– | Mélanome | IV | Paclitaxel ; Carboplatine | |
| II | Cancer de l’ovaire | |||||
| Sarcome | ||||||
| Cancer du pancréas | IT | Gemzar | ||||
| Cancer colorectal | IV | – | ||||
| ONYX-015 (ONYX pharmaceuticals) |
E1B 55k (-) ; E3B (-) | II | Cancer hépatobiliaire | IT | – | |
| Cancer colorectal, pancréas | IA | – | ||||
| Cancer cervico-facial | IT | Cisplatine ; 5-Fluorouracile | ||||
| Adénovirus | ||||||
| Oncorine H101 (Shangai sunway biotech) |
E1B 55k (-) ; E3 (-) | III | Cancer cervico-facial | IT | Cisplatine | |
| II | Cancer cervico-facial | |||||
| CG0070 | E2F1, GM-CSF | II/III | Cancer de la vessie | Intracavité | ||
| Coxsackie virus | CAVATAK | – | II | Mélanome | Intracavité | – |
| Newcastle disease virus | OV001 | – | I/II | Glioblastome multiforme, sarcome, neuroblastome |
IV | – |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.